• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Bangalore, Nov. 20

Avesthagen Ltd said its intellectual property portfolio for diabetes management has been valued at an average of $470 million (over Rs 2000 crore) by a leading global life sciences analyst. Dr Villoo Morawala Patell, Founder Chairman and Managing Director of Avesthagen, said, “This evaluation positions us strongly in the market and the compounds that we are developing will prevent and provide relief to diabetics across the world.” In the near future, this IP wi ll find application in three market segments – functional foods, dietary supplements and nutraceuticals – areas on which the company is focussing, according to an Avesthagen release.

– Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line